^
    1year
    ALK-negative anaplastic large cell lymphoma with JAK2 rearrangement mimicking classic Hodgkin lymphoma | Blood | American Society of Hematology https://t.co/r3X6TfGAVp (@ixazebe)
    ALK (Anaplastic lymphoma kinase) • JAK2 (Janus kinase 2)
    |
    ALK negative • JAK2 rearrangement
    2years
    Great work by @FordePatrick & colleagues. This trial has now established clear role for #immunotherapy in almost all stages of #EGFR/#ALK negative #NSCLC (early-stage neoadjuvant; early-stage adjuvant; locally advanced; metastatic). #PDL1 expression correlated w/ outcomes in all! (@ns_chd)
    Clinical • IO biomarker
    |
    EGFR (Epidermal growth factor receptor) • PD-L1 (Programmed death ligand 1) • ALK (Anaplastic lymphoma kinase)
    |
    PD-L1 expression • ALK negative
    2years
    Based on the recent neo-adjuvant data and approval of Chemo-IO (#CM816) for Stage Ib-IIIA NSCLC, EGFR/ALK negative, what would you be doing in your clinical practice? In neo-adj settings, would you offer: #LCSM @FordePatrick @n8pennell @CharuAggarwalMD @JackWestMD @DrJNaidoo (@OncBrothers)
    Clinical
    |
    EGFR (Epidermal growth factor receptor)
    |
    ALK negative
    2years
    Similar situation now with a 50 yo male former smoker, no other comorbidities. lung adenocarcinoma, EGFR/ALK negative, PD-L1 20%. Stage IIIB (T4N2 by 7th and 8th AJCC Ed) VATS RUL lobectomy after neoadjuvant chemo-IO. pCR Remains NED (cc’d @DoctorJSpicer: again no N2 pics 🙏) (@Tony_Calles)
    Clinical
    |
    EGFR (Epidermal growth factor receptor) • PD-L1 (Programmed death ligand 1)
    |
    PD-L1 negative • ALK negative
    almost3years
    IMPACT OF DUSP22 REARRANGEMENT ON THE PROGNOSIS OF SYSTEMIC ALK-NEGATIVE ANAPLASTIC LARGE CELL LYMPHOMA: A LYSA AND TENOMIC STUDY. Largest study to date... no impact of DUSP22 rearr on PFS. #16icml https://t.co/JI27UQtgUx (@timfenske)
    ALK (Anaplastic lymphoma kinase)
    |
    ALK negative